for reasons such as high development and marketing

for reasons such as high development and marketing costs, patients’ access to them can be limited. Biosimilars have… https://t.co/GHEwJTzL43

Dr. George Williams joins as we take a Deep Dive i

Dr. George Williams joins as we take a Deep Dive into
#bevacizumab biosimilars for eye conditions. @BiosimCenter… https://t.co/neDyrPJJNA

Symptoms of #CrohnsDisease and #UlcerativeColitis are not limited to the gut. Help make #IBDVisible by sharing what… https://t.co/tQO5sUvDmb

Looking forward to reviewing @HHSGov’s recommendations regarding patient access to and uptake of #bisomilars.… https://t.co/i3C7b5HeOs

If you have #IBD you probably suffer from joint #pain and #fatigue. #Exercise is the last thing we want to do when… https://t.co/ZS1kv9DcIX

Daily Updates on Generic Entry, Litigation, Biosimilars, and more with the DrugPatentWatch Daily Briefing. Sign up… https://t.co/BncfqAvNtY

Optimization of healthcare systems would increase access and promote greater biosimilar competition, benefitting al… https://t.co/r6ai6ieR5V

Catch up on the most-read biosimilar stories of the past week. Pfizer’s commitment to #biosimilars, Biden’s war on… https://t.co/QfCQiIDBjF

Three-year overall survival did not differ between DLBCL patients treated with rituximab biosimilars and those rece… https://t.co/1sC24EiQDC